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Abstract 
Aims. Although aberrant DNA methylation has been described in rheumatoid arthritis 
(RA), no studies have interrogated this epigenetic modification in early disease. 
Following recent investigations of T- and B-lymphocytes in established disease, we 
now characterize in these cell populations genome-wide DNA methylation in treatment-
naïve patients with early RA. 
Patients & Methods. HumanMethylation450 BeadChips were used to examine 
genome-wide DNA methylation in lymphocyte populations from 23 early RA patients 
and 11 healthy individuals.  
Results. Approximately 2,000 CpGs in each cell type were differentially methylated in 
early RA. A novel methylation signature in each cell type (150 sites in T-lymphocytes, 
113 sites in B-lymphocytes) perfectly distinguished patients from controls. A subset of 
sites differentially methylated in early RA displayed similar changes in established 
disease. 
Conclusions. Treatment-naïve early RA patients display novel disease-specific DNA 
methylation aberrations, supporting an important role for these changes in the 
pathogenesis of RA. 
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Introduction 
Rheumatoid arthritis (RA) is a common autoimmune inflammatory joint disease that 
affects between 0.5 and 1% of the adult population [1, 2]. Estimates of disease 
incidence for the UK indicate in the region of 20,000 new RA cases each year [3], the 
majority of whom begin treatment with one or more disease modifying anti-rheumatic 
drugs. The disease is characterized by chronic inflammation and progressive destruction 
of synovial joint tissues, and a compelling literature now implicates alterations to the 
epigenome in the pathogenesis of RA. These alterations are multifactorial and include 
those that impact on DNA methylation, histone modifications and the expression of 
microRNAs [reviewed in 4-6].  
 
DNA methylation describes the addition of a methyl group to the nucleobase cytosine, 
most frequently in the context of cytosine-guanine dinucleotides (CpGs). Inappropriate 
methylation of these sites in promoter-associated regions is frequently associated with 
gene silencing, whereas in transcriptionally competent genes these sites are commonly 
not methylated [7]. Changes to the DNA methylome have been described in multiple 
cell types in patients with RA. Global levels of methylation, for example, are altered in 
peripheral blood mononuclear cells and lymphocytes from patients with RA [8-11]. In 
addition, candidate gene studies also describe aberrant methylation across multiple, 
discrete, genes in these cell types [12-18]. Further to these studies, and in this case using 
genome-wide methylation arrays, we recently reported disease-associated methylation 
changes in multiple genes that were distinct to individual T- and B-lymphocyte 
populations [19]. Similar findings in the context of alterations to the epigenome are also 
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apparent in fibroblast-like synoviocytes derived from the joint [20-27], which further 
supports an important role for altered methylation in the pathogenesis of RA. 
 
To date, studies of DNA methylation have been reported for patients with established 
RA, in many of these cases at the time of joint replacement. These patients have 
typically been treated over prolonged periods with a variety of disease-modifying 
agents, including methotrexate, a cornerstone of therapy in RA. However, a potential 
impact of methotrexate on DNA methylation has been suggested in RA and similar 
conditions [7, 28, 29]. Changes to the epigenome identified in established RA may 
therefore reflect, at least in part, the impact of treatment and the burden of chronic 
inflammation present during the evolution and progression of the disease. Thus, and as 
noted by others [30], such confounders have precluded identification of methylation 
changes that are important drivers of disease in RA. Indeed, to our knowledge, there has 
been no systematic examination of DNA methylation in patients with early disease, or 
in those at first diagnosis and who are naïve for treatment with disease-modifying anti-
rheumatic drugs. 
 
In this report, and in contrast to previous studies from our own and other laboratories, 
we have investigated genome-wide DNA methylation in T- and B-lymphocyte 
populations from newly diagnosed, treatment-naïve patients with RA. Our studies in 
these patients mitigate the likely impact of disease evolution and of different treatment 
modalities and their associated sequela apparent in established disease. In this way, the 
identified methylation changes are likely to reflect those associated with disease 
development and pathogenesis.  
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Patients & Methods 
Patients 
Genome-wide DNA methylation was investigated in 23 Caucasian patients recruited 
consecutively from the early synovitis clinic at the Haywood Rheumatology Centre in 
Stoke-on-Trent, UK, and also in a group of 11 healthy Caucasian females, the details of 
which we have previously reported [19]. All patients had symptomatic inflammatory 
arthritis suspected to be RA at presentation, and subsequently were classified with RA 
by a consultant rheumatologist and according to the 2010 ACR/EULAR classification 
criteria [31]. Demographic data and clinical characteristics for the patients are presented 
in Table 1. All patients were naïve for treatment with disease modifying anti-rheumatic 
drugs and biological therapies. With two exceptions, all patients had active disease at 
recruitment based on a disease activity score with 28-joint counts (DAS28) [32] ≥ 3.2, 
and approximately half (44%) had high disease activity (DAS28 > 5.1). The average age 
of the patients and healthy control group was 58.9 ± 15.8 years and 52.6 ± 4.9 years, 
respectively (mean ± SD). All study participants gave written informed consent. The 
study was approved by the East Midlands (Derby) Research Ethics Committee. 
 
Purification of T- and B-lymphocyte populations 
Whole blood samples (35 ml, EDTA) were collected from each patient at recruitment 
and prior to the start of treatment. Peripheral blood mononuclear cells were prepared 
using density-gradient centrifugation (Histopaque-1077, Sigma Aldrich). Thereafter, 
CD19+ B-lymphocytes and CD3+ T-lymphocytes were isolated from the mononuclear 
cell fraction by positive selection using anti-CD19 and anti-CD3 magnetic microbeads, 
respectively. All isolations were performed according to the manufacturer’s instructions 
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(MiniMACS® Separation System; Miltenyi Biotec). Cells were pelleted, lysed (Buffer 
RLT Plus; Qiagen), and homogenized (QIAShredder spin columns; Qiagen) prior to 
storage at -80°C. We have previously demonstrated this method of cell isolation to yield 
high purity T-lymphocyte (≥99%) and B-lymphocyte (≥90%) populations from patients 
with RA and healthy individuals alike [19, 33]. 
 
Genome-wide DNA methylation profiling 
HumanMethylation450 BeadChips (Illumina Inc.; hereafter referred to as ‘array’ or 
‘450K array’) were used to profile genome-wide DNA methylation at more than 
480,000 CpG sites in lymphocyte populations from patients and healthy individuals. 
Genomic DNA was extracted from cell lysates according to the manufacturer’s 
instructions using an AllPrep DNA/RNA/miRNA Universal kit (Qiagen), with further 
concentration by ethanol-based precipitation. DNA samples were sodium bisulfite 
treated and hybridized to 450K arrays according to manufacturer recommended 
protocols (performed by Hologic Tepnel Pharma Services, UK) that we have described 
previously [33]. Methylation at individual CpGs is reported as a β-value [34] on a linear 
scale, where 0 and 1 indicate unmethylated and completely methylated sites, 
respectively. 
 
Sodium bisulfite pyrosequencing 
Independent quantification of methylation at array-identified candidate CpG loci was 
conducted by sodium bisulfite pyrosequencing. For this purpose, amplicons containing 
CpGs of interest were prepared from whole-genome amplified, bisulfite-converted DNA 
using a touchdown PCR process, as we have described previously [33]. Oligonucleotide 
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primers for all PCR and pyrosequencing reactions were designed using PyroMark Assay 
Design software (Qiagen) and were specific for bisulfite-converted DNA. Primers were 
purchased from Biomers.net and assay details are provided in Supplementary Table 1. 
Pyrosequencing was performed according to the manufacturer’s recommendations using 
a PyroMark Q24 instrument (Qiagen). Assays included one or more control 
dispensations to confirm successful bisulfite conversions. All data were analyzed using 
PyroMark Q24 software (v 2.0.6., build 20; Qiagen). 
 
Data analysis 
Processing and analysis of array data to determine methylation differences between 
treatment-naive early RA patients and healthy individuals was performed using idat 
files and the Bioconductor package Minfi [35]. Each array passed initial quality control 
assessment based on the performance of internal array controls. For each of the T- and 
B-lymphocyte array datasets, we excluded from analysis all probes located on the X and 
Y chromosomes and probes with a detection p-value > 0.01 in any one or more of the 
samples (n = 34 [23 patients and 11 healthy controls]). Array data were subsequently 
normalized using Subset-quantile Within Array Normalization (SWAN) [36], an 
approach which has been shown to reduce technical variation both within and between 
arrays, including the technical differences observed between the two different probe 
types on the array [34, 37]. Following these steps, a total of 470,366 and 473,105 CpGs 
in T-lymphocytes and B-lymphocytes, respectively, were retained and were used in 
subsequent analyses. 
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For each of the cell types separately, the ‘dmpFinder’ function in Minfi was used to 
identify CpGs that were differentially methylated between treatment-naïve early RA 
patients and healthy individuals (step 1, Figure 1). This function performs an F-test to 
test the equality of means and was used with logit transformed β-values (M-values), as 
recommended by Du et al [38]. The false discovery rate (FDR) [39] was used to adjust 
for multiple testing, with adjusted p-values < 0.05 considered statistically significant. 
 
In addition to the analysis described above, sites identified as differentially methylated 
in treatment-naïve early RA patients relative to healthy individuals were further 
examined through comparison with methylation in patients with established disease. In 
these cases, we used the processing and normalization procedures described above to re-
analyze the 450K array data derived from a cohort of established RA patients (n = 12) 
that we have previously described [19]. Criteria to identify sites (a) differentially 
methylated in both early and established RA relative to healthy individuals, and (b) 
showing altered methylation in established but not early RA, are described in the 
Results and Figure 1 (steps 2 and 3). 
 
Patterns of differential methylation within and between groups were examined by 
hierarchical clustering using Genesis software (v1.7.6) with Euclidian distance and 
complete linkage criteria [40]. Further statistical analyses were performed using Stata 
8.0 (Intercooled; Stata Corporation, TX, USA). P-values < 0.05 were considered 
significant. 
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Results 
Genome-wide DNA methylation is altered in treatment-naïve early RA 
We investigated genome-wide DNA methylation in T- and B-lymphocytes from a 
cohort of RA patients recruited at diagnosis and who were naïve for treatment with 
disease-modifying anti-rheumatic therapies. On the basis of a difference in mean β-
value ≥ 0.1, and as described in Step 1 of Figure 1, we identified 1,951 CpGs in T-
lymphocytes and 2,238 CpGs in B-lymphocytes that showed methylation changes in 
early RA patients relative to healthy individuals. These sites, the majority of which 
(60%) were hypermethylated in each of the cell types, represented 1,216 and 1,362 
unique genes in T- and B-lymphocytes, respectively. Summary characteristics for these 
sites are presented in Supplementary Table 2 (a complete list of CpGs for each cell 
type are available in Supplementary Tables 3 and 4). 
 
Further analysis across the differentially methylated sites revealed a subset of 150 CpGs 
in T-lymphocytes and 113 CpGs in B-lymphocytes that showed more substantial 
methylation differences (≥ 0.2) in early RA patients relative to their healthy 
counterparts (step 2, Figure 1). A summary of these sites is provided in Table 2 and 
annotated lists of the sites are provided in Supplementary Tables 5 and 6. Hierarchical 
clustering methodology was used to determine whether methylation patterns across 
these sites could distinguish between patients with early RA and healthy individuals. As 
shown graphically by the heatmaps and dendrograms in Figure 2, analysis revealed that 
differentially methylated sites in T- and B-lymphocytes segregate without exception 
early RA patients from healthy individuals. Indeed, there were 8 CpGs in T-
lymphocytes and 12 CpGs in B-lymphocytes that showed methylation changes in all 23 
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early RA patients, and over 40 sites in each cell type were differentially methylated in 
80% or more of the patients (Supplementary Figure 1). Of particular note in this 
analysis, of the 150 and 113 CpGs identified in T- and B-lymphocytes respectively, 44 
sites shared identify between the cell types; moreover, for each of these sites, the 
direction of change in methylation was the same in each of the cell types. 
 
Array data for selected CpG sites were validated by bisulfite pyrosequencing analysis. 
In each case, we observed concordance between array β-values and methylation values 
determined by this technique, reinforcing our conclusions of differential methylation in 
treatment-naïve early RA patients relative to healthy controls. Figure 3 shows examples 
of two sites in T-lymphocytes (DUSP22 and KCNJ5) and one site in B-lymphocytes 
(ADAMTS17). In addition, and as previously reported by us [19, 33], a significant 
correlation between the two methods was apparent across the spectrum of methylation 
β-values (Figure 3A). 
 
Discrete methylation changes in early RA are preserved in patients with 
established disease 
We next examined the methylation status of the 150 and 113 CpGs identified in T- and 
B-lymphocytes from early RA patients in a group of 12 patients with established disease 
that we have previously described [19]. For each of these patients, disease was of at 
least 5-years duration and in some cases extended to 30 years. In that study, and using 
the same array platform, we observed significant heterogeneity in methylation β-values 
across the patient samples, which we interpret may reflect the impact of disease 
progression or treatment modalities in these patients. We therefore assessed methylation 
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at the CpGs identified in early disease in each of the 12 established RA patients on an 
individual basis. Employing the criteria shown in Step 3 of Figure 1, we identified 50 
and 26 CpGs in T- and B- lymphocytes, respectively, that showed methylation changes 
in both established and early disease (blue boxes, Figure 1). Examples of gene-
associated CpGs identified in T-lymphocytes (DUSP22, KCNJ5 and MAGI2) and B-
lymphocytes (MAML3) are shown in Figure 4 (a complete list and annotation for these 
sites is provided in Supplementary Tables 7 and 8). 
 
Discrete methylation changes in established, but not early, disease 
Finally, we determined whether methylation changes specifically associated with 
disease progression were also apparent. In these cases, we reasoned that these changes 
would be present in established disease but not in early RA patients. To this end, and as 
described in Step 1 of Figure 1, we first identified those sites for which there we no 
statistically significant differences in methylation between treatment-naïve early RA 
patients and healthy individuals. We subsequently identified CpGs differentially 
methylated in established disease as those for which six or more patients displayed 
altered methylation relative to, in these cases, both the early RA and healthy control 
groups (step 3, Figure 1). Using this approach, we identified 218 CpGs in T-
lymphocytes and 208 CpGs in B-lymphocytes that were aberrantly methylated and were 
unique to patients with established disease (green boxes, Figure 1; details for these 
sites are provided in Supplementary Tables 9 and 10). Examples of the genes 
identified in T-lymphocytes (BANF2) and B-lymphocytes (PSORS1C3, PCDH12 and 
JRK) are presented in Figure 5. Validation of selected genes by pyrosequencing 
confirmed the methylation changes observed by array in all cases (data not shown).  
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Discussion 
The pathogenic mechanisms that drive disease in RA are not completely understood but 
an expanding literature implicates an important role for aberrations to the epigenome, 
including those which impact on the DNA methylation [4-7]. However, and to our 
knowledge, studies focusing on DNA methylation in RA, including those from our own 
laboratory, have been restricted to patients with established disease and, by extension, 
subsequent to long-standing therapeutic intervention. These potential confounders, and 
others consequent to disease progression, have thus far precluded identification of 
aberrantly methylated loci that play an important role in the etiology and genesis of RA, 
as has recently been discussed in RA [30, 41] and related conditions [42, 43]. 
 
In an attempt to address these issues, we determined genome-wide DNA methylation 
profiles in a cohort of newly diagnosed treatment-naïve patients with RA. Using 
stringent analytical and statistical criteria, we have identified novel disease-associated 
methylation changes in enriched T- and B-lymphocyte populations from these patients. 
These changes to the epigenome in treatment-naive early disease (relative to healthy 
controls) target multiple genes, suggesting an important role for specific epigenetic 
modification in the genesis and etiology of RA. Through comparison of these new data 
in early RA with data from our earlier, similar work in patients with established disease 
[19], we further report methylation changes present in early RA that are preserved in 
established disease. Similarly, we have also determined additional changes to the 
methylome that appear to be confined to or specific to patients with established disease. 
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The initial finding of our work was the identification of 1,951 CpGs in T-lymphocytes 
and 2,238 CpGs in B-lymphocytes, representing 1,216 and 1,362 genes respectively, 
that were differentially methylated in patients with early RA relative to healthy controls. 
The overall number of CpGs we identified are similar to those reported in studies of 
genome-wide methylation in RA patients with established disease [25, 26]. Applying 
more stringent criteria to the dataset (specifically β-value differences ≥0.2), we 
identified 150 and 113 sites in T- and B-lymphocytes respectively that discriminated 
between and segregated all of the early RA patients from healthy controls. To our 
knowledge, we are the first to define discrete methylation signatures in RA using 
distinct T- and B-lymphocyte populations; interestingly, methylation patterns in T-
lymphocytes have previously been shown to segregate patients from controls in other 
autoimmune conditions [44]. 
 
Importantly, we found that the methylation changes defining each signature in T- and B-
lymphocytes were present in the majority of patients studied. Indeed, there were more 
than 30 sites in each cell type that showed aberrant methylation in 20 or more of the 23 
patients; for some of these sites, differential methylation was apparent in all 23 of the 
patients investigated. Furthermore, for each individual patient, 70 or more of the 150 
sites identified in T-lymphocytes, and a similar number of the 113 sites identified in B-
lymphocytes, were inappropriately methylated. The identification of methylation 
changes at these sites, and in particular those that are present in all or nearly all patients, 
supports a potential role for these as “drivers” of disease, rather than as “passenger” 
methylation events, a concept that has been described in cancer epigenetics [45, 46]. We 
also identified in early RA a further subset of sites (n = 44) that were differentially 
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methylated in both the T- and B-lymphocyte populations. Moreover, for each of these 
sites the direction of the methylation change, hypermethylation or hypomethylation, was 
identical in each cell type. These sites therefore appear to reflect lymphocyte-specific, 
rather than cell subset-specific, methylation changes that are associated with RA.  
 
Comparative analyses of our findings in early disease with methylation levels 
determined in patients with established RA led to the identification of a significant 
number of sites where methylation changes in treatment-naïve early RA were also 
apparent in established disease. Aberrant methylation at these sites was apparent in at 
least six of the 12 established RA patients. These findings in both early and established 
disease suggest that epigenetic dysregulation at these sites/genes may be important in 
the establishment and maintenance of the disease phenotype. Conversely, we also 
identified a subset of sites for which differential methylation was apparent in patients 
with established RA but not in those newly diagnosed with RA. These changes, again 
present in at least six of the 12 established RA patients, might reflect changes important 
in disease progression, or perhaps be consequent to disease progression, chronic 
inflammation [47] and responses to individual treatment modalities. They may also 
reflect, in part, the influence of inherent heterogeneity between patients, and may thus 
represent the “passenger” methylation changes discussed earlier. 
 
Examination of the differentially methylated sites using gene ontology and pathway 
analysis did not identify any specific ontology/pathway terms that were significantly 
enriched in early RA (following adjustment for multiple testing; data not shown). 
Nevertheless, amongst the sites aberrantly methylated in early RA, and in this case also 
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in patients with established disease, we noted multiple sites within the gene for 
DUSP22, a protein tyrosine phosphatase for which aberrant methylation has also been 
described in autoimmune primary Sjögren’s syndrome [42]. Sites within this gene were 
hypermethylated in 21 of the 23 early RA patients and in 10 of 12 patients with 
established disease. Amongst other actions, DUSP22 has been reported to negatively 
regulate STAT3 and the IL-6/STAT3 signaling pathway [48] that mediates the actions 
of IL-6, a key cytokine in RA [49]. A recent study has also demonstrated enhanced T-
lymphocyte-mediated immune responses and spontaneous development of 
autoimmunity and inflammation in a DUSP22 knockout mouse model, suggesting an 
important suppressive role in the regulation of T-lymphocyte-mediated immunity and 
autoimmunity [50]. Together, these findings support a potential role for epigenetic-
mediated dysregulation of DUSP22 that may be important in the development and 
progression of RA. 
 
The potential impact on the DNA methylome of treatment, and as a potential 
confounder, has been recognized by us [19, 27] and other investigators [10, 28, 30]. 
Methotrexate, the first-line anti-rheumatic drug in RA [51], has been reported to be 
associated with global methylation levels in inflammatory arthritis [10], and 
discordance for treatment with methotrexate has been shown to significantly impact on 
identification of differentially methylated sites in juvenile idiopathic arthritis [28]. More 
recently, methotrexate has been shown to induce demethylation of the Foxp3 locus in 
regulatory T-lymphocytes [29], cells essential for immunological self-tolerance [52] and 
the development of which is known to be epigenetically controlled [53]. Given these 
findings, we considered it important to focus our investigation on a cohort of patients 
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who were naïve for treatment with disease-modifying anti-rheumatic drugs, including 
methotrexate. In doing so, we are able to specifically exclude the likely impact of these 
agents from our findings and the identification of candidate CpGs/genes in this study.  
 
The patients studied in this work were recruited consecutively from the early synovitis 
clinic at the hospital, with a subsequent diagnosis of RA in all cases. Through this 
approach we were able to study DNA methylation at first diagnosis and prior to the start 
of treatment. A potential caveat associated with our findings is the impact of 
confounding. However, and in this context, we were able to mitigate the influence of 
race and age, previously associated with DNA methylation [54, 55], by studying 
Caucasian subjects in whom the mean ages of early RA patients and healthy individuals 
were closely matched. To address the inclusion of both male and female patients, we 
removed prior to analysis all CpGs located on the X and Y chromosomes, as we and 
others have previously described [36, 56]. Furthermore, clustering analysis did not 
define separate clusters within the early RA group contingent on gender (data not 
shown). An important next step will be for the methylation signatures reported here to 
be replicated and verified by us and other groups in independent cohorts of newly 
diagnosed treatment-naïve patients. 
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Conclusions 
Our findings reveal, for the first time, genome-wide aberrant DNA methylation in 
treatment-naïve patients newly diagnosed with RA. These changes in methylation, 
identified using a stringent genome-wide array approach and independent of treatment, 
are present in individual T- and B-lymphocyte populations and define unique disease-
associated methylation signatures. Altered methylation for a subset of the sites is also 
preserved in patients with established disease. These data support an important role for 
aberrant methylation within discrete lymphocyte populations in the development and 
pathogenesis of RA. This work provides an incentive for further investigations in 
patients with early RA, most notably, to explore the potential of these epigenetic 
profiles to be used to predict treatment response and inform the clinical management of 
this condition. 
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Executive Summary 
Background 
• Compelling evidence from studies of multiple cell types describes changes to the 
DNA methylome in patients with rheumatoid arthritis (RA).  
• Studies to date have examined patients with long-term established disease, which 
has precluded the identification of aberrant methylation signals associated with the 
etiology of RA. 
• This study examined genome-wide DNA methylation in a cohort of treatment-naive 
patients with newly diagnosed early RA. 
Patients & Methods 
• Genome-wide DNA methylation profiling using HumanMethylation450 BeadChips 
was performed in individual T- and B-lymphocyte populations from 23 treatment-
naive patients with early RA and 11 healthy controls. 
• Array data were processed and differentially methylated sites identified using Minfi. 
Sites identified in early RA were further examined in patients with established 
disease (n = 12). Validation was conducted by bisulfite pyrosequencing. 
Results 
• Differential methylation in early RA was identified at 1,951 CpGs in T-lymphocytes 
and 2,238 CpGs in B-lymphocytes, representing 1,216 and 1,362 genes respectively. 
• Sites displaying more substantial changes in methylation (≥ 0.2 difference) perfectly 
segregated early RA patients and healthy individuals into two discrete groups. 
• A subset of sites differentially methylated in early RA showed similar methylation 
changes in established disease also. Conversely, sites were also identified for which 
methylation was altered in established, but not early, RA. 
20 
 
Conclusions 
• Our findings for the first time reveal genome-wide DNA methylation changes and a 
unique methylation signature in individual T- and B-lymphocyte populations that 
are present at first diagnosis in patients with RA. 
• Aberrant methylation of the candidates identified is independent of confounding 
from disease-modifying treatments in this cohort of treatment-naïve patients. 
• These data support an important role for aberrant methylation within discrete 
lymphocyte populations in the development of RA. Further work is needed to 
confirm our findings and explore DNA methylation in the context of treatment 
response and the clinical management of RA. 
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Figure legends 
Figure 1. Filtering criteria for identification of CpGs differentially methylated in 
treatment-naïve early RA patients relative to healthy individuals. The starting 
number of CpGs indicated for T-lymphocytes and B-lymphocytes (470,366 and 
473,105, respectively) are the sites remaining after processing and normalization, as 
described in the Methods. Numbers in the figure indicate the number of CpGs 
remaining at each successive step, and where: 1) red boxes indicates sites differentially 
methylated in early RA relative to healthy individuals; 2) blue boxes indicate sites 
differentially methylated in early RA and also in established RA (relative to healthy); 
and 3) green boxes indicate sites differentially methylated in established RA but not in 
early RA (relative to healthy).  
 
Figure 2. Heatmap and clustering for the 150 and 113 differentially methylated 
CpGs in T- and B-lymphocytes, respectively, in treatment-naïve early RA patients. 
For T-lymphocytes (A) and B-lymphocytes (B), each row represents an individual CpG 
and each column an individual sample (listed beneath the heatmap). Color gradation 
from yellow to blue represents low to high DNA methylation respectively, with β-
values ranging from 0 (no methylation; yellow) to 1 (complete methylation; blue). In 
both cell types, methylation patterns across these sites segregated RA patients (red bar) 
and healthy individuals (green bar) into two discrete groups. 
 
Figure 3. Validation of differentially methylated CpGs in T- and B-lymphocytes in 
treatment-naive early RA patients. A. Scatter plot demonstrating excellent correlation 
between array methylation β-values and methylation as determined by bisulfite 
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pyrosequencing for T- and B-lymphocytes from treatment-naive early RA patients. One 
CpG in each of three separate genes was analyzed (HMOX2, cg14951292; AMN, 
cg09616556; and PM20D1, cg11965913). Spearman’s r = 0.964, p < 0.00001. (Data for 
patients with established RA and healthy individuals was reported previously [16]). B–
D. Validation using bisulfite pyrosequencing of two hypermethylated candidates in T-
lymphocytes, DUSP22 (B) and KCNJ5 (C), and one hypomethylated candidate in B-
lymphocytes, ADAMTS17 (D), showing differential methylation in early RA relative to 
healthy individuals. In each plot, early RA patients (n = 23) and healthy individuals (n = 
11) are depicted by circles and triangles respectively, and the short blue horizontal bar 
in each group indicates the mean value. Gene names are shown on the x-axis and where, 
for each gene, methylation values are shown for the array (filled symbols; left) and 
pyrosequencing (open symbols; right). 
 
Figure 4. Identification of differentially methylated sites in early RA that also show 
altered methylation in patients with established disease. Shown are examples of 
three candidates in T-lymphocytes, DUSP22 (A), KCNJ5 (B) and MAGI2 (C), and one 
candidate in B-lymphocytes, MAML3 (D), that were identified by array analysis as 
differentially methylated in early RA, and which also showed similar methylation 
changes in patients with established disease (criteria for differential methylation in each 
RA group relative to healthy individuals are described in the main text). In each plot, 
RA patients (early and established) and healthy individuals are depicted by circles and 
triangles respectively. Filled circles in the early and established RA groups represent 
individual samples showing a methylation level at least 20% higher/lower than the mean 
of the healthy group for hypermethylated and hypomethylated sites, respectively 
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(indicated by the horizontal dashed line). The short blue horizontal bar in each group 
indicates the mean value. CpGs are presented by their associated gene in each case 
(shown on the x-axis). 
 
Figure 5. Identification of sites differentially methylated in established RA that are 
not differentially methylated in patients with early RA. Shown are examples of one 
candidate in T-lymphocytes, BANF2 (A), and three candidates in B-lymphocytes, 
PSORS1C3 (B), PCDH12 (C), and JRK (D), that displayed similar levels of methylation 
in early RA patients and healthy individuals but which were identified as differentially 
methylated in patients with established disease (criteria for differential methylation in 
established RA are described in the main text). In each plot, RA patients (early and 
established) and healthy individuals are depicted by circles and triangles respectively. 
Filled circles in the established RA group represent individual samples showing a 
methylation level at least 20% higher or lower than the mean of the healthy group for 
hypermethylated and hypomethylated sites, respectively (indicated by the horizontal 
dashed line). The short blue horizontal bar in each group indicates the mean value. 
CpGs are presented by their associated gene in each case (shown on the x-axis). For 
each gene, a minimum of six established RA patients showed a methylation difference ≥ 
0.2 relative to the healthy and early RA groups. The differential methylation observed 
was also reflected by a mean difference ≥ 0.2 in the established RA group relative to the 
means of the healthy and early RA groups.  
 
Supplementary Figure 1. Heatmap of methylation differences in individual early 
RA patients, relative to the healthy control group mean, for each of the 150 and 
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113 CpGs differentially methylated in T- and B-lymphocytes, respectively. For T-
lymphocytes (A) and B-lymphocytes (B), each row represents an individual CpG and 
each column an individual treatment-naïve early RA patient (listed above the heatmap). 
For each patient, sites hypomethylated and hypermethylated relative to the mean of the 
healthy group are depicted by blue and red coloring, respectively (grey indicates sites 
not differentially methylated relative to healthy controls). The black horizontal line 
separates sites hypomethylated (above) and hypermethylated (below) in early RA. CpGs 
are ordered according to the total number of individual patients showing a methylation 
difference relative to the healthy mean (decreasing from top to bottom for 
hypomethylated sites, and increasing from top to bottom for hypermethylated sites). 
 
Supplementary Table 1. Assay details for candidate CpGs/genes interrogated by 
bisulfite pyrosequencing. 
*Further information that is not included here is available upon request. The horizontal 
dashed line between rows 7 and 8 separates candidate genes in T-lymphocytes (above) 
and B-lymphocytes (below). 
†The prefix 'b-' denotes biotin labeling at the 5' end. 
‡The sequence provided is post-bisulfite conversion. Letters 'Y' and 'R' denote the 
cytosine of the CpG site interrogated by the assay ('Y' and 'R' refer to sequencing along 
the upper and lower strands respectively). 
Abbreviations: bp, base pairs 
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Supplementary Table 2. Summary characteristics for CpGs identified as 
differentially methylated in T-lymphocytes and B-lymphocytes in treatment-naïve 
early RA patients.* 
Unless otherwise indicated, all figures are the number (%). 
* Differentially methylated CpGs were identified according to the criteria described in 
the Methods/Results section and in Figure 1 (sites with a mean difference in β-value ≥ 
0.1 that was statistically significant). 
† Annotation describing CpG island, shore and shelf status, and genetic location relative 
to defined gene regions, is derived from the University of California at Santa Cruz 
(UCSC) database. 
Abbreviations: TSS200, 200-bp block upstream of the transcription start site; TSS1500, 
1500-bp block upstream of the transcription start site; 5’ UTR, 5’ untranslated region; 3’ 
UTR, 3’ untranslated region. 
 
Supplementary Table 3. Complete list, β-value data and annotation for the 1,951 
CpGs identified in T-lymphocytes as differentially methylated between treatment-
naïve early RA patients and healthy individuals.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 1,239 and 1,240 separates CpGs that were hypermethylated (above) 
and hypomethylated (below) in T-lymphocytes from treatment-naive early RA patients. 
†The 'dmpFinder' function in Minfi [35] was used to calculate F-test p-values adjusted 
for multiple testing using the false discovery rate (FDR) [39]. 
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Supplementary Table 4. Complete list, β-value data and annotation for the 2,238 
CpGs identified in B-lymphocytes as differentially methylated between treatment-
naïve early RA patients and healthy individuals.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 1,295 and 1,296 separates CpGs that were hypermethylated (above) 
and hypomethylated (below) in B-lymphocytes from treatment-naive early RA patients. 
†The 'dmpFinder' function in Minfi [35] was used to calculate F-test p-values adjusted 
for multiple testing using the false discovery rate (FDR) [39]. 
 
Supplementary Table 5. Complete list, β-value data and annotation for the 150 
CpGs identified in T-lymphocytes as differentially methylated (≥ 0.2 mean 
difference) between treatment-naïve early RA patients and healthy individuals.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 92 and 93 separates CpGs that were hypermethylated (above) and 
hypomethylated (below) in T-lymphocytes from treatment-naive early RA patients. 
†The 'dmpFinder' function in Minfi [35] was used to calculate F-test p-values adjusted 
for multiple testing using the false discovery rate (FDR) [39]. 
 
Supplementary Table 6. Complete list, β-value data and annotation for the 113 
CpGs identified in B-lymphocytes as differentially methylated (≥ 0.2 mean 
difference) between treatment-naïve early RA patients and healthy individuals.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 95 and 96 separates CpGs that were hypermethylated (above) and 
hypomethylated (below) in B-lymphocytes from treatment-naive early RA patients. 
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†The 'dmpFinder' function in Minfi [35] was used to calculate F-test p-values adjusted 
for multiple testing using the false discovery rate (FDR) [39]. 
 
Supplementary Table 7. Complete list, β-value data and annotation for the 50 
CpGs in T-lymphocytes that were differentially methylated in treatment-naïve 
early RA and which also were differentially methylated in patients with established 
RA.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 36 and 37 separates CpGs that were hypermethylated (above) and 
hypomethylated (below) in T-lymphocytes from both treatment-naive early RA patients 
and from patients with established disease. 
 
Supplementary Table 8. Complete list, β-value data and annotation for the 26 
CpGs in B-lymphocytes that were differentially methylated in treatment-naïve 
early RA and which also were differentially methylated in patients with established 
RA.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 25 and 26 separates CpGs that were hypermethylated (above) and 
hypomethylated (below) in B-lymphocytes from both treatment-naive early RA patients 
and from patients with established disease. 
 
Supplementary Table 9. Complete list, β-value data and annotation for the 218 
CpGs in T-lymphocytes that were not differentially methylated in treatment-naïve 
early RA but were differentially methylated in patients with established RA.* 
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*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 121 and 122 separates CpGs that were hypermethylated (above) and 
hypomethylated (below) in T-lymphocytes from patients with established RA. 
 
Supplementary Table 10. Complete list, β-value data and annotation for the 208 
CpGs in B-lymphocytes that were not differentially methylated in treatment-naïve 
early RA but were differentially methylated in patients with established RA.* 
*Unless otherwise stated, values are array methylation β-values. The dashed horizontal 
line between rows 103 and 104 separates CpGs that were hypermethylated (above) and 
hypomethylated (below) in B-lymphocytes from patients with established RA. 
 
 
